Legislative and regulatory barriers to pharmacies dispensing buprenorphine for OUD DOI
Daniel Strickland,

Jordon T Baker

Journal of Opioid Management, Journal Year: 2023, Volume and Issue: 19(7), P. 135 - 140

Published: Oct. 18, 2023

Buprenorphine (BUP) is increasingly recognized and utilized as a valuable medication for the treatment of opioid use disorder. This article focuses on problem regulatory restrictions access to buprenorphine products without naloxone (mono-product), involving patients in one geographic area, but which may represent more general United States.In response an audit by Tennessee Board Pharmacy, pharmacy northeast designed questionnaire survey patient motivation traveling long distances fill their prescriptions BUP, rather than buprenorphine/naloxone (BNx, combo-product), document satisfaction with mono-product.Questionnaires were submitted 194 patients, living Tennessee, southwest Virginia, southeast Kentucky. Significant, intolerable, side effects reported all prescribed BNx, because legislative respective states, they unable obtain BUP closer home. Consequently, required drive significant from homes prescriptions, median distance 52 miles, some cases far 216 miles round trip. Intolerable reactions included severe headaches, nausea vomiting, allergies, dysphoria. All tolerated clinically well maintained mono-product.Severe, intolerable reactions/side component BNx are not uncommon, mono-product prohibit providers pharmacies states prescribing dispensing BUP. The participants this qualitative study found it necessary travel medication, thereby potentially limiting life-saving therapy.

Language: Английский

Pharmacy Harm Reduction Practices to Help Reduce Opioid Overdoses, Arizona 2023 DOI Creative Commons
Beth E. Meyerson,

Sergio Richter,

Ross Gordon

et al.

Journal of the American Pharmacists Association, Journal Year: 2025, Volume and Issue: unknown, P. 102348 - 102348

Published: Feb. 1, 2025

Characterizing pharmacies based on their practices, community need for such practices and pharmacy type could advance pharmacy-based intervention precision to reinforce or increase related reducing opioid overdose deaths. To measure a combination of 3 focused death reduction explore whether there are discernable groupings characteristics, characteristics. A telephone survey was conducted between August 1, 2023 October 8, with the pharmacist duty at 921 Arizona pharmacies. The measured buprenorphine stocking, naltrexone dispensing, likelihood methadone dispensing use disorder (OUD) when legally permitted, interest in state-subsidized naloxone dispensing. response rate 22.6% achieved (N = 208). vast majority (93.8%) stocked dispensed naltrexone. About half (47.6%) were very likely somewhat dispense OUD permitted. Metropolitan less compared rural (45.1% Vs. 75.0%). Among not methadone, 85.3% located counties rates above national average. indicated enrolling as distributor naloxone. When considered together 26% reported frequent expressed subsidized Latent class analysis yielded 4 distinct groups ranging from those only frequently adopters community. 'adopters' who naltrexone, had naloxone, would tended be metropolitan small/rural areas but mass merchandizers. An emerging group shows potential greater adoption reduce overdose. Larger, multistate studies will help verify latent practice interventions communities. It is crucial why higher adopt reduction.

Language: Английский

Citations

0
Addressing buprenorphine bottlenecks in the context of MAT Act implementation: A shared responsibility DOI
Bayla Ostrach, Lucas G. Hill, Delesha M. Carpenter

et al.

Journal of the American Pharmacists Association, Journal Year: 2023, Volume and Issue: 63(4), P. 1044 - 1048

Published: May 4, 2023

Language: Английский

Citations

9
The impact of the mainstreaming addiction treatment act and associated legislative action on pharmacy practice DOI
Tyler J. Varisco, Matthew A. Wanat, Lucas G. Hill

et al.

Journal of the American Pharmacists Association, Journal Year: 2023, Volume and Issue: 63(4), P. 1039 - 1043

Published: April 23, 2023

Language: Английский

Citations

7
Independent community pharmacists’ attitudes and intentions toward dispensing buprenorphine/naloxone for opioid use disorder DOI

Rana Zalmai,

Lucas G. Hill, Lindsey J. Loera

et al.

Journal of the American Pharmacists Association, Journal Year: 2023, Volume and Issue: 63(5), P. 1558 - 1565.e4

Published: June 16, 2023

Language: Английский

Citations

7
Incidence of buprenorphine‐precipitated opioid withdrawal in adults with opioid use disorder: A systematic review DOI
Caroline Gregory, Krishan Yadav,

Jordyn Linders

et al.

Addiction, Journal Year: 2024, Volume and Issue: 120(1), P. 7 - 20

Published: Sept. 25, 2024

Buprenorphine is an evidence-based treatment for opioid use disorder, and the risk of precipitated withdrawal contributes to its underuse. The goal this systematic review was determine incidence buprenorphine-precipitated in adults with disorder.

Language: Английский

Citations

2
Mapping Buprenorphine Access at Philadelphia Pharmacies DOI
Shoshana V. Aronowitz, Rachel French,

Allison Schachter

et al.

Journal of Addiction Medicine, Journal Year: 2024, Volume and Issue: 18(3), P. 269 - 273

Published: Feb. 12, 2024

Objectives Buprenorphine is not reliably stocked in many pharmacies, and pharmacy-level barriers may deter patients from opioid use disorder care. We surveyed all outpatient pharmacies Philadelphia to describe variation buprenorphine access developed a map application aid identifying that stock the medication. Methods Using dataset Bureau of Professional Occupational Affairs, we conducted telephone survey operating (N = 422) about their stocking dispensing practices. used ArcGIS Pro 3.0.3 join US Census ZIP code-level race ethnicity data, conduct descriptive analyses, create application. Results collected data 351 (83% response rate). Two hundred thirty-eight (68%) indicated they regularly buprenorphine; 6 (2%) would order it when prescription sent. Ninety-one (26%) said do or buprenorphine, 16 (5%) were unsure. identified 137 “easier access” (39%), meaning dispense new patients, have no dosage maximums. Zip codes with predominantly White residents had median (interquartile range) 3 (2–4) those Black 2 (1–4.5). Nine zip only one; these are areas residents. Conclusions equitable across quarter choose carry Our be identify buprenorphine.

Language: Английский

Citations

1
Nurse Practitioner Work Environment and Rural Primary Care for Substance Use DOI
Eleanor Turi, Amy McMenamin, Suzanne E. Courtwright

et al.

The Journal for Nurse Practitioners, Journal Year: 2024, Volume and Issue: 20(9), P. 105152 - 105152

Published: July 20, 2024

Language: Английский

Citations

1
Addressing the Escalating Problems That Patients Encounter When Filling Buprenorphine Prescriptions DOI
Erin L. Winstanley,

A. M. H. Gray,

J. Douglas Thornton

et al.

JAMA Psychiatry, Journal Year: 2024, Volume and Issue: unknown

Published: Oct. 16, 2024

This Viewpoint describes both the current barriers patients face when filling their prescriptions for buprenorphine at pharmacies and a list of proposed fixes requiring changes federal, state, insurance, clinician level.

Language: Английский

Citations

1
Descriptive study: the novel “full spectrum people-with-opioid-use-disorder care model” DOI Creative Commons

Richard Gadomski,

Snehal Bhatt, Jessica Gross

et al.

Harm Reduction Journal, Journal Year: 2023, Volume and Issue: 20(1)

Published: April 12, 2023

People with Opioid Use Disorder (PWOUD) represent an underserved and marginalized population for whom treatment gaps exist. Low-barrier programs like mobile care units street outreach have yielded increased access to buprenorphine social services, however, OUD pertinent co-occurring behavioral health medical conditions are frequently left unaddressed. A novel, tailored, comprehensive delivery model may reduce disparities improve across a range of pathologies in this historically difficult reach enhance efforts provide universal harm reduction setting.Descriptive data were collected analyzed regarding patient demographics, retention services rendered at new, wrap-around, low-barrier clinic established existing site New Mexico between August 1, 2020, 31, 2021.203 people used any service the newly implemented program, 137 specifically obtained and/or including prescriptions least once from physician onsite. Thirty-seven unique psychiatric treated, representing total 565 separate encounters. The most common utilized was opioid use disorder (81%), followed by post-traumatic stress (62%), anxiety (44.5%) depression (40.9%). Retention 31.2% 6 months.An innovative, multidisciplinary, buprenorphine-centric model, which targets wide while employing approach, can utilization these among PWOUD manner moves our system toward thereby potentially reducing overdose disparities.

Language: Английский

Citations

2
Assessing suboxone access in community pharmacies: Secret shopper model DOI Creative Commons
Bethany A. DiPaula, Catherine E. Cooke

Exploratory Research in Clinical and Social Pharmacy, Journal Year: 2023, Volume and Issue: 12, P. 100356 - 100356

Published: Nov. 3, 2023

To assess whether Maryland community pharmacies had Suboxone available for dispensing.This cross-sectional study used a secret shopper model to contact public-facing in Maryland. The shopper, guided by script, asked prescription was the same or next day pick-up. A small convenience sample of who did not have received an in-person visit inquire about medication availability and dispensing barriers.After contacting 99% (n = 1046) pharmacies, confirmed immediate pick-up 31% 326). remaining have, would disclose, limited access (existing patients specific providers only). Significant differences were found National Capital vs. Baltimore metro region when pharmacist questions no questions. Of 11 pharmacy visits completed, 10 said they currently stock, with one clarifying existing only.About 69% may face challenges calling find out can obtain pharmacies. Better patient education more thorough pharmacy-level investigation system workflow barriers could offer solutions.

Language: Английский

Citations

2